Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Friedlaender

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
Frontiers in Oncology|July 1, 2022
Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung CancerEmilio Francesco Giunta, Alessio Signori, Howard Jack West, et al.
Pharmacology & Therapeutics|January 12, 2023
RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectivesAlfredo Addeo, Ernesto Miranda-Morales, Petra den Hollander, et al.
The Canadian Journal of Cardiology|December 26, 2017
Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for CardiologistsMauro Frigeri, Philippe Meyer, Carlo Banfi, et al.
Expert Review of Respiratory Medicine|January 31, 2024
First-line immunotherapy in non-small cell lung cancer: how to select and where to goAndrea Mogavero, Ornella Cantale, Veronica Mollica, et al.
Critical Reviews in Oncology/Hematology|September 10, 2022
Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitorsSara Elena Rebuzzi, Arsela Prelaj, Alex Friedlaender, et al.
Human Vaccines & Immunotherapeutics|May 18, 2021
Immune checkpoint inhibitors for unresectable malignant pleural mesotheliomaGiulio Metro, Diego Signorelli, Elio G Pizzutilo, et al.
Translational Lung Cancer Research|September 21, 2020
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumabGiuseppe Luigi Banna, Diego Signorelli, Giulio Metro, et al.
Journal of Gastrointestinal Oncology|March 14, 2024
Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in miceXin Zhou, Minjie Yang, Jiaze Yu, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2023
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastasesPamela Trillo, Josè Sandoval, Dario Trapani, et al.
Current Oncology Reports|October 18, 2022
Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung CancerGiuseppe Luigi Banna, Alex Friedlaender, Marco Tagliamento, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Frontiers in Oncology|July 1, 2022
Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung CancerEmilio Francesco Giunta, Alessio Signori, Howard Jack West, et al.
Pharmacology & Therapeutics|January 12, 2023
RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectivesAlfredo Addeo, Ernesto Miranda-Morales, Petra den Hollander, et al.
The Canadian Journal of Cardiology|December 26, 2017
Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for CardiologistsMauro Frigeri, Philippe Meyer, Carlo Banfi, et al.
Expert Review of Respiratory Medicine|January 31, 2024
First-line immunotherapy in non-small cell lung cancer: how to select and where to goAndrea Mogavero, Ornella Cantale, Veronica Mollica, et al.
Critical Reviews in Oncology/Hematology|September 10, 2022
Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitorsSara Elena Rebuzzi, Arsela Prelaj, Alex Friedlaender, et al.
Human Vaccines & Immunotherapeutics|May 18, 2021
Immune checkpoint inhibitors for unresectable malignant pleural mesotheliomaGiulio Metro, Diego Signorelli, Elio G Pizzutilo, et al.
Translational Lung Cancer Research|September 21, 2020
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumabGiuseppe Luigi Banna, Diego Signorelli, Giulio Metro, et al.
Journal of Gastrointestinal Oncology|March 14, 2024
Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in miceXin Zhou, Minjie Yang, Jiaze Yu, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2023
Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastasesPamela Trillo, Josè Sandoval, Dario Trapani, et al.
Current Oncology Reports|October 18, 2022
Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung CancerGiuseppe Luigi Banna, Alex Friedlaender, Marco Tagliamento, et al.
Pageof 11